SI3275871T1 - Kristali - Google Patents

Kristali

Info

Publication number
SI3275871T1
SI3275871T1 SI201031997T SI201031997T SI3275871T1 SI 3275871 T1 SI3275871 T1 SI 3275871T1 SI 201031997 T SI201031997 T SI 201031997T SI 201031997 T SI201031997 T SI 201031997T SI 3275871 T1 SI3275871 T1 SI 3275871T1
Authority
SI
Slovenia
Prior art keywords
crystals
Prior art date
Application number
SI201031997T
Other languages
English (en)
Inventor
Hideyuki Itou
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3275871(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of SI3275871T1 publication Critical patent/SI3275871T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SI201031997T 2009-06-26 2010-06-25 Kristali SI3275871T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009151727 2009-06-26
JP2009151728 2009-06-26
JP2009151729 2009-06-26
EP17186415.0A EP3275871B1 (en) 2009-06-26 2010-06-25 Crystals

Publications (1)

Publication Number Publication Date
SI3275871T1 true SI3275871T1 (sl) 2020-06-30

Family

ID=43386634

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201031634T SI2447254T1 (sl) 2009-06-26 2010-06-25 Kristali
SI201031997T SI3275871T1 (sl) 2009-06-26 2010-06-25 Kristali

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201031634T SI2447254T1 (sl) 2009-06-26 2010-06-25 Kristali

Country Status (33)

Country Link
US (4) US8791122B2 (sl)
EP (3) EP3689855A1 (sl)
JP (1) JPWO2010150865A1 (sl)
KR (2) KR20170024165A (sl)
CN (2) CN104326991A (sl)
AR (1) AR077242A1 (sl)
AU (1) AU2010263569B2 (sl)
BR (2) BR122021005510B1 (sl)
CA (1) CA2764475C (sl)
CL (1) CL2011003264A1 (sl)
CO (1) CO6430432A2 (sl)
CY (3) CY1119788T1 (sl)
DK (2) DK2447254T3 (sl)
ES (2) ES2797124T3 (sl)
HK (1) HK1244788A1 (sl)
HR (2) HRP20180171T1 (sl)
HU (3) HUE036721T2 (sl)
IL (3) IL216928A (sl)
LT (3) LT2447254T (sl)
MA (1) MA33637B1 (sl)
MX (2) MX2011013471A (sl)
MY (1) MY186531A (sl)
NO (2) NO2447254T3 (sl)
NZ (1) NZ597352A (sl)
PH (2) PH12015502824A1 (sl)
PL (2) PL3275871T3 (sl)
PT (2) PT2447254T (sl)
RU (1) RU2556206C3 (sl)
SG (2) SG176915A1 (sl)
SI (2) SI2447254T1 (sl)
TW (1) TWI531565B (sl)
WO (1) WO2010150865A1 (sl)
ZA (1) ZA201109099B (sl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959868A (zh) * 2008-02-28 2011-01-26 日本新药株式会社 纤维化抑制剂
US8575175B2 (en) * 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
WO2017040872A1 (en) 2015-09-03 2017-03-09 Teva Pharmaceuticals International Gmbh Solid state forms of selexipag
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
SG11201804320QA (en) 2015-12-02 2018-06-28 Nippon Shinyaku Co Ltd Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
US10815204B2 (en) 2016-04-01 2020-10-27 Honour (R&D) Process for the preparation of diphenylpyrazine derivatives
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
CA3029960A1 (en) 2016-07-05 2018-01-11 Maithri Drugs Private Limited Novel process for the preparation of 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018022704A1 (en) * 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
CN108069914A (zh) * 2016-11-17 2018-05-25 江苏艾立康药业股份有限公司 一种西里帕格晶型的制备方法
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
MX2020000999A (es) 2017-07-27 2020-07-22 Allergan Inc Agonistas del receptor de prostacyclin para reducir la grasa corporal.
AR112842A1 (es) 2017-09-28 2019-12-18 Nippon Shinyaku Co Ltd Cristal de pirazina
US10407396B2 (en) 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
US11382912B2 (en) 2017-11-16 2022-07-12 Nippon Shinyaku Co., Ltd. Controlled-release preparation
WO2019154363A1 (zh) 2018-02-07 2019-08-15 南京明德新药研发有限公司 前列环素受体受体激动剂
JP7430629B2 (ja) * 2018-02-21 2024-02-13 日本新薬株式会社 粒状組成物、粒状組成物の製造方法、および粒状組成物の溶出性改善方法
CN109125325B (zh) 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
EP3705115B1 (en) 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
US20220331313A1 (en) 2019-05-06 2022-10-20 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
US20220257594A1 (en) 2019-05-21 2022-08-18 Actelion Pharmaceuticals Ltd Transitioning patients treated for pulmonary arterial hypertension to selexipag
EP3982967A1 (en) 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Methods for treating pulmonary arterial hypertension
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
WO2021078835A1 (en) 2019-10-23 2021-04-29 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
US20230032813A1 (en) 2019-11-29 2023-02-02 Actelion Pharmaceuticals Ltd Methods of treating pulmonary arterial hypertension
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics Inc LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
WO2021152060A1 (en) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
US20230073428A1 (en) 2020-02-03 2023-03-09 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
CN112500358B (zh) * 2020-11-18 2022-03-15 江苏豪森药业集团有限公司 赛乐西帕晶型及其制备方法
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092760A1 (en) 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
EP1106176B1 (en) 1999-05-10 2008-06-18 Toray Industries, Inc. Remedies for renal failure
PT1178047E (pt) 2000-08-03 2004-05-31 Pfizer Prod Inc Derivados diazabiciclooctano e seus usos terapeuticos
US20040116530A1 (en) * 2001-04-18 2004-06-17 Noriaki Maeda Tissue fibrosis inhibitors
TWI316055B (sl) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US20060189695A1 (en) 2003-06-25 2006-08-24 Cardiovascular Institute, Ltd External preparation for improving coital function
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
CN101959868A (zh) 2008-02-28 2011-01-26 日本新药株式会社 纤维化抑制剂
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
WO2009157398A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 炎症性腸疾患治療剤
CA2728089C (en) 2008-06-23 2017-04-11 Nippon Shinyaku Co., Ltd. Therapeutic agent for spinal canal stenosis
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
BRPI0918134B1 (pt) 2008-09-10 2019-02-12 Kaken Pharmaceutical Co., Ltd Derivado de prostaglandina i2

Also Published As

Publication number Publication date
US20140155414A1 (en) 2014-06-05
PT3275871T (pt) 2020-04-21
JPWO2010150865A1 (ja) 2012-12-10
MX346318B (es) 2017-03-15
DK2447254T3 (en) 2018-01-15
DK3275871T3 (da) 2020-04-06
AR077242A1 (es) 2011-08-10
ES2660007T3 (es) 2018-03-20
AU2010263569A1 (en) 2012-02-02
SG10201403313WA (en) 2014-10-30
WO2010150865A1 (ja) 2010-12-29
EP3689855A1 (en) 2020-08-05
RU2556206C3 (ru) 2021-06-15
PH12015502825B1 (en) 2017-12-11
IL243287A0 (en) 2016-02-29
PL3275871T3 (pl) 2020-07-27
CN102459198B (zh) 2014-09-24
HRP20180171T1 (hr) 2018-03-09
RU2012102678A (ru) 2013-08-10
CY2018011I2 (el) 2018-09-05
CA2764475C (en) 2017-04-25
US8791122C1 (sl) 2014-07-29
MA33637B1 (fr) 2012-10-01
CY2018011I1 (el) 2018-09-05
HUS1800015I1 (hu) 2018-05-28
IL216928A (en) 2016-10-31
SG176915A1 (en) 2012-01-30
BRPI1015936B1 (pt) 2021-07-13
CO6430432A2 (es) 2012-04-30
LT2447254T (lt) 2018-01-10
CL2011003264A1 (es) 2012-07-06
CY1119788T1 (el) 2018-06-27
NZ597352A (en) 2013-01-25
CN104326991A (zh) 2015-02-04
BR122021005510B1 (pt) 2022-01-11
EP2447254A1 (en) 2012-05-02
US20120101276A1 (en) 2012-04-26
EP3275871B1 (en) 2020-01-15
AU2010263569B2 (en) 2016-08-18
PT2447254T (pt) 2018-01-04
HK1244788A1 (zh) 2018-08-17
EP2447254A4 (en) 2012-12-19
EP2447254B1 (en) 2017-12-06
PL2447254T3 (pl) 2018-05-30
TWI531565B (zh) 2016-05-01
EP3275871A1 (en) 2018-01-31
US9284280B2 (en) 2016-03-15
NO2447254T3 (sl) 2018-05-05
HUE036721T2 (hu) 2018-07-30
US9440931B2 (en) 2016-09-13
CA2764475A1 (en) 2010-12-29
KR20170024165A (ko) 2017-03-06
SI2447254T1 (sl) 2018-03-30
KR20120109457A (ko) 2012-10-08
ES2797124T3 (es) 2020-12-01
US8791122B2 (en) 2014-07-29
BRPI1015936A2 (pt) 2016-08-16
PH12015502824A1 (en) 2017-05-29
IL243293A0 (en) 2016-02-29
LT3275871T (lt) 2020-05-11
US20140148469A1 (en) 2014-05-29
MX2011013471A (es) 2012-01-30
CN102459198A (zh) 2012-05-16
RU2556206C2 (ru) 2015-07-10
IL243287B (en) 2021-04-29
US20150266830A1 (en) 2015-09-24
CY1122893T1 (el) 2021-05-05
HUE048467T2 (hu) 2020-07-28
PH12015502825A1 (en) 2017-12-11
TW201111352A (en) 2011-04-01
IL216928A0 (en) 2012-02-29
LTPA2018008I1 (lt) 2018-05-10
MY186531A (en) 2021-07-25
LTC2447254I2 (lt) 2022-04-25
NO2018015I1 (no) 2018-04-23
ZA201109099B (en) 2012-08-29
HRP20200539T1 (hr) 2020-07-10
US9340516B2 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
HUS1800015I1 (hu) Kristályok
DK3023438T3 (en) Anti-gitr-antistoffer
ZA201105462B (en) Crystalline insulin-conjugates
HK1168791A1 (en) Substituted imidazoquinoxalines
GB201103481D0 (en) No details
GB201016096D0 (en) No details
GB201016097D0 (en) No details
HK1174617A1 (en) Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts -1----2---
EP2456311A4 (en) SUBSTITUTED IMIDASOTRIAZINES
ZA201108565B (en) Substituted piperidnes
EP2448583A4 (en) SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES
GB0912999D0 (en) Method-803
GB0908006D0 (en) New crystal form
GB2540489B (en) Killswitch
EP2448584A4 (en) Substituted 4-hydroxypropyl-5-carboxamide
AU4240P (en) Tuckerbox xTriticosecale
AU4925P (en) Bonscawi Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
AU324442S (en) Keylight
AP00242S1 (en) Woodstove
GB0910235D0 (en) 2Locusafe
GB0912660D0 (en) 5Chopperstopper
AU2009190V (en) SILSUN Chrysocephalum apiculatum
AU329913S (en) Cupcan
AP2009000321S (en) Doropak